Mouse models (that develop or can be stimulated to develop lymphomas) are used to examine cancer-related processes. Mouse models can be effective tools used to identify new, early, and pre-malignant markers of lymphomas. Signal Transducer and Activator of Transcription (STAT) 6 is a transcription factor activated through the Jak-Stat pathway. Transgenic mice expressing a constantly activated Stat6 (Stat6VT) were previously generated and characterized to have altered lymphocyte homeostasis. Some of these Stat6VT mice developed a lymphoproliferative disorder (LPD). LPD, including lymphomas, develops when lymphocytes are overproduced or act abnormally. These Stat6VT mice may serve as a model for examining lymphoma development. In order to characterize the altered lymphocytes and determine if LPD observed in the Stat6VT mice is characteristic of lymphoma, RT-PCR analysis and Western analysis were done to examine if the presence of Stat6VT alters the expression of the cell cycle genes Gfi-1 and Gfi-1b and if these genes differ in LPD Stat6VT verses control mice. / Department of Biology

Stat6 is a protein that activates the transcription of IL-4-stimulated genes. Amino acids critical for Stat6 function were examined in a mutational analysis of the Src homology (SH2) domain of the Stat6 protein. One mutation, substitution of two Alanines for Valine and Threonine in the N-terminal portion of the SH2 domain, produced a constitutively active form of the molecule that did not require IL-4 for activation. This mutant was named Stat6VT. Mice expressing Stat6VT in lymphocytes were generated, and it was found that approximately 10% of the population of Stat6VT mice, a lympho-proliferative disorder (LPD) occurred. In this study, we are examining genes that have a possible role in the development of this proliferative condition. Specifically, we examined the expression levels of Tiam1, Tacstdl, and Gfi-1 and Gfi-1B (genes known to regulate cellular proliferation and survival) in wildtype, normal Stat6VT and Stat6VT/LPD splenocytes by RT-PCR. Tiam1 results were inconclusive, and Tacstdl was not expressed at levels different from those seen in controls. Interestingly, Gfi-1 B, the homolog of Gfi-1, was expressed at increased levels in a specific subpopulation of cells from Stat6VT/LPD mice. Taken together, these data suggest that in cells expressing a constitutively active Stat6, increased expression of Gfi-1B may play a role in the mechanism of lymphoma development. / Department of Biology

Diss. (sammanfattning) Uppsala : Uppsala universitet, 2007. / Härtill 5 uppsatser.

Made available in DSpace on 2014-12-17T14:14:03Z (GMT). No. of bitstreams: 1 AldairSP_DISSERT.pdf: 3401140 bytes, checksum: 29fad07626595e61c30bdf3a90539133 (MD5) Previous issue date: 2014-02-26 / Chronic lymphoproliferative disorders (DLPC) are lymphoid system diseases characterized by the abnormal proliferation of mature lymphocytes that affect B cells, T lymphocytes and NK cells. The aim of the study was to demonstrate the relevance of immunophenotyping by flow cytometry in patients with prolonged lymphocytosis and / or cytomorphological changes compatible with lymphoproliferative diseases. In this study 460 patients (244 men and 216 women) with DLPC were evaluated. Were analyzed by flow cytometry with a panel of monoclonal antibodies consisting of CD3, CD4, CD5, CD8, CD10, CD19, CD22, CD23, CD25, CD38, CD45, CD16/CD56, and HLADR heavy and light chains of immunoglobulins. It also examines information regarding age, gender of patients and laboratory data as leucocytes, cytomorphological analysis, platelet count and hemoglobin determination. The results showed 398 cases of chronic lymphoproliferative disorders and 62 of DLPC B cell lymphoproliferative diseases T. B showed the following distribution : 253 cases of chronic lymphocytic leukemia (CLL), 42 cases of multiple myeloma ( MM ), 37 cases of lymphoma non - Hodgkin lymphoma in leukemic phase (NHL) , 17 cases of pro- B lymphocytic leukemia ( B -PLL), 15 cases of mantle cell lymphoma (MCL ), 12 cases of plasma cell leukemia ( PCL), 9 cases of lymphoma Burkitt (Linf B), 8 cases of leukemia villous cells ( LCV), 3 cases of splenic lymphoma with villous cells (LECV), a case of follicular lymphoma (LF) and a Waldenstr?n macroglobulinemia ( MW). The diseases source NK / T were 23 cases of peripheral T cell lymphoma (LCTP), 14 cases of T prolymphocytic leukemia (T -PLL), 10 cases of leukemia T of large granular lymphocytes (LGL -T) 9 cases of leukemia cells of adult T (LCTA), 5 cases of Sezary syndrome (SS) and a case of large granular NK leukemia (LGL -NK) lymphocytes. In conclusion, the combined use of the monoclonal antibody panel careful cytomorphological analysis was shown to be essential in immune diagnosis and classification of chronic lymphoproliferative disorders. This study was approved by the IRB - HUOL under number 356 / 09 / Os transtornos linfoproliferativos cr?nicos (DLPC) s?o doen?as do sistema linfoide caracterizadas pela prolifera??o anormal de linf?citos maduros que acometem c?lulas B, linf?citos T e c?lulas NK. O objetivo do estudo foi demonstrar a relev?ncia da imunofenotipagem por citometria de fluxo em pacientes portadores de linfocitose prolongada e/ou altera??es citomorfol?gicas compat?veis com doen?as linfoproliferativas. Neste estudo foram avaliados 460 pacientes (244 homens e 216 mulheres) com DLPC. Foram analisados por citometria de fluxo com um painel de anticorpos monoclonais constitu?do por CD3, CD4, CD5, CD8, CD10, CD19, CD22, CD23, CD25, CD38, CD45, CD16/CD56, HLADR e cadeias leves e pesadas de imunoglobulinas. Foram tamb?m investigadas informa??es referentes ? idade, ao g?nero dos pacientes e aos dados laboratoriais como: leucometria, an?lise citomorfol?gica, contagem de plaquetas e determina??o da hemoglobina. Os resultados demonstraram 398 casos de doen?as linfoproliferativas cr?nicas B e 62 de DLPC de c?lula T. As doen?as linfoproliferativas B apresentaram a seguinte distribui??o: 253 casos de leucemia linfoc?tica cr?nica (LLC), 42 casos de mieloma m?ltiplo (MM), 37 casos de linfoma n?o Hodgkin em fase leuc?mica (LNH), 17 casos de leucemia pr?-linfoc?tica B (LPL-B), 15 casos de linfoma de c?lulas do manto (LCM), 12 casos de leucemia de c?lulas plasm?ticas (LCP), 9 casos de linfoma de Burkitt (Linf B), 8 casos de leucemia de c?lulas vilosas (LCV), 3 casos de linfoma espl?nico de c?lulas vilosas (LECV), um caso de linfoma folicular (LF) e um de macroglobulinemia de Waldenstr?n (MW). As doen?as de origem T/NK foram: 23 casos de linfoma de c?lulas T perif?ricas (LCTP), 14 casos de leucemia pr?linfoc?tica T (LPL-T), 10 casos de leucemia de grandes linf?citos T granulares (LGLT), 9 casos de leucemia de c?lulas T do adulto (LCTA), 5 casos de S?ndrome de Sezary (SS) e um caso de leucemia de grandes linf?citos NK granulares (LGL-NK). Em conclus?o, o uso do painel de anticorpos monoclonais combinado ? an?lise citomorfol?gica cuidadosa mostrou-se essencial no diagn?stico e classifica??o imune das doen?as linfoproliferativas cr?nicas. O presente estudo foi aprovado pelo CEP HUOL sob n?mero 356/09

京都大学 / 新制・課程博士 / 博士(医学) / 甲第23421号 / 医博第4766号 / 新制||医||1053(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 小濱 和貴, 教授 妹尾 浩, 教授 川口 義弥 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Nas últimas décadas, verificou-se diferenças nas classificações da World Health Organization (WHO) de 2001 e da European Organization for Research and Treatment of Cancer (EORTC) de 1997 para os linfomas cutâneos primários. Em 2005, representantes dessas classificações se reuniram e em consenso estabeleceram a classificação WHO-EORTC que foi adotada pela última classificação da WHO de 2008. O presente estudo visa a avaliar a aplicabilidade dessa nova classificação em casuística retrospectiva de um único centro de referência no diagnóstico e tratamento de linfomas cutâneos. Assim, todos os casos de linfoma cutâneo de células T, excluindo-se micose fungóide (MF) e síndrome de Sézary (SS), no período de 1986 a 2009, foram analisados em relação aos aspectos clínicos, histopatológicos e imunofenotípicos, incluindo-se a realização de novas reações imunoistoquímicas. Os casos foram, então, classificados de acordo com critérios estabelecidos na classificação WHO de 2008. Houve, assim, 33 casos de linfomas cutâneos de células T não-MF e não-SS, sendo 08 (24,2%) de linfoma cutâneo de grandes células anaplásicas, 05 (15,2%) de papulose linfomatóide, 06 (18,1%) de linfoma extranodal de células NK/T tipo nasal, 05 (15,2%) de neoplasia de células dendríticas plasmocitóides blásticas, 05 (15,2%) de linfoma/leucemia de células T do adulto e 04 (12,1%) de linfoma de células T periféricas, sem outra especificação. Portanto, a classificação WHO de 2008 é aplicável à maioria dos casos de linfoma cutâneo de células T não-MF e não-SS. Entretanto, permanecem casos não classificáveis, alguns dos quais com curso clínico agressivo / Recent years have witnessed differences between the World Health Organization (WHO) 2001 and the European Organization for Research and Treatment of Cancer (EORTC) 1997 classification systems of primary cutaneous lymphomas (PCLs). In 2005, a joint WHO-EORTC classification system for PCLs has been reached and was adopted by last WHO 2008 classification. This study was performed to assess the applicability of this new classification to a single referral center. All cutaneous T-cell lymphoma (CTCL) cases, excluding mycosis fungoides (MF) and Sezary syndrome (SS), who were referred from 1986 to 2009 were included. The clinical features, histological and immunohistochemical stainings were reviewed, and additional stains were performed as needed. The cases were then reclassified according to the WHO 2008 classification. There were 33 cases of non-MF and non-SS CTCL, included 08 (24.2%) CD30+ anaplastic large-cell lymphomas, 05 (15.2%) cases of lymphomatoid papulosis, 06 (18.1%) extranodal NK/T-cell lymphoma nasal type, 05 (15.2%) blastic plasmacytoid dendritic cell neoplasm, 05 (15.2%) adult T-cell lymphoma/leukemia and 04 (12.1%) peripheral T-cell lymphomas, unspecified. The new WHO 2008 classification is applicable to most nonMF and non-SS CTCL cases. However, there is still a substantial subset of T-cell PCLs which cannot be classified beyond the unspecified peripheral T-cell category, some of which may have an aggressive course

Thesis (Ph.D.) -- University of Texas Southwestern Medical Center at Dallas, 2006. / Not embargoed. Vita. Bibliography: 181-228.

Nas últimas décadas, verificou-se diferenças nas classificações da World Health Organization (WHO) de 2001 e da European Organization for Research and Treatment of Cancer (EORTC) de 1997 para os linfomas cutâneos primários. Em 2005, representantes dessas classificações se reuniram e em consenso estabeleceram a classificação WHO-EORTC que foi adotada pela última classificação da WHO de 2008. O presente estudo visa a avaliar a aplicabilidade dessa nova classificação em casuística retrospectiva de um único centro de referência no diagnóstico e tratamento de linfomas cutâneos. Assim, todos os casos de linfoma cutâneo de células T, excluindo-se micose fungóide (MF) e síndrome de Sézary (SS), no período de 1986 a 2009, foram analisados em relação aos aspectos clínicos, histopatológicos e imunofenotípicos, incluindo-se a realização de novas reações imunoistoquímicas. Os casos foram, então, classificados de acordo com critérios estabelecidos na classificação WHO de 2008. Houve, assim, 33 casos de linfomas cutâneos de células T não-MF e não-SS, sendo 08 (24,2%) de linfoma cutâneo de grandes células anaplásicas, 05 (15,2%) de papulose linfomatóide, 06 (18,1%) de linfoma extranodal de células NK/T tipo nasal, 05 (15,2%) de neoplasia de células dendríticas plasmocitóides blásticas, 05 (15,2%) de linfoma/leucemia de células T do adulto e 04 (12,1%) de linfoma de células T periféricas, sem outra especificação. Portanto, a classificação WHO de 2008 é aplicável à maioria dos casos de linfoma cutâneo de células T não-MF e não-SS. Entretanto, permanecem casos não classificáveis, alguns dos quais com curso clínico agressivo / Recent years have witnessed differences between the World Health Organization (WHO) 2001 and the European Organization for Research and Treatment of Cancer (EORTC) 1997 classification systems of primary cutaneous lymphomas (PCLs). In 2005, a joint WHO-EORTC classification system for PCLs has been reached and was adopted by last WHO 2008 classification. This study was performed to assess the applicability of this new classification to a single referral center. All cutaneous T-cell lymphoma (CTCL) cases, excluding mycosis fungoides (MF) and Sezary syndrome (SS), who were referred from 1986 to 2009 were included. The clinical features, histological and immunohistochemical stainings were reviewed, and additional stains were performed as needed. The cases were then reclassified according to the WHO 2008 classification. There were 33 cases of non-MF and non-SS CTCL, included 08 (24.2%) CD30+ anaplastic large-cell lymphomas, 05 (15.2%) cases of lymphomatoid papulosis, 06 (18.1%) extranodal NK/T-cell lymphoma nasal type, 05 (15.2%) blastic plasmacytoid dendritic cell neoplasm, 05 (15.2%) adult T-cell lymphoma/leukemia and 04 (12.1%) peripheral T-cell lymphomas, unspecified. The new WHO 2008 classification is applicable to most nonMF and non-SS CTCL cases. However, there is still a substantial subset of T-cell PCLs which cannot be classified beyond the unspecified peripheral T-cell category, some of which may have an aggressive course

La variante lymphocytaire du syndrome hyperéosinophilique (L-SHE) est une pathologie extrêmement rare caractérisée par une prolifération monoclonale de lymphocytes T surproduisant l’interleukine IL-5, responsable d’une hyperéosinophilie persistante. En outre, un immunophénotype aberrant CD3−CD4+ est fréquemment observé à la surface des cellules T clonales. Cette pathologie se distingue par une lymphoprolifération chronique indolente habituellement révélée par une hyperéosinophilie sanguine et une infiltration éosinophilique des tissus cutanés. Toutefois, l’évolution vers un lymphome T observée chez certains patients suggère la présence d’un potentiel malin des cellules T. Ce modèle représente donc une rare opportunité d’identifier les changements moléculaires liés aux différentes étapes du processus transformant lymphoïde T.<p>Dans le cadre de ce travail, nous avons cherché à établir les caractéristiques cytogénétiques et moléculaires des cellules T CD3−CD4+ d’une cohorte de patients L-SHE. L’analyse cytogénétique de cellules T CD3−CD4+ isolées au moment du diagnostic chez deux patientes (P1 et P2) a révélé la présence d’une délétion similaire 6q13-q22.1. En étudiant les stades cliniques successifs de P1 et P2, nous avons montré la persistance des cellules porteuses de la délétion 6q au cours de la progression chronique et leur prédominance lors du développement d’un lymphome T chez P1. Ces résultats suggèrent l’implication précoce et potentiellement critique de la délétion 6q dans cette pathologie lymphoproliférative T. L’analyse des dérégulations transcriptionnelles résultant de ce remaniement a montré une réduction de l’expression des gènes pro-apototiques BACH2 et PA26 dans les cellules T CD3−CD4+ de P1 et P2. En particulier, BACH2, dont l’expression diminue continuellement au cours de l’évolution de P1, jouerait un rôle oncosuppresseur dans la lymphogenèse T.<p>Afin d’identifier les modifications moléculaires des cellules T clonales, nous avons analysé l’expression de 95% des gènes humains dans les cellules T CD3−CD4+ de trois patients en phase chronique (P1, P2 et P3). La grande homologie des changements transcriptionnels chez les trois patients indique une altération des mêmes mécanismes moléculaires. Ainsi, un profil immunophénotypique exhaustif, validé chez trois patients supplémentaires, a pu être établi. En outre, les dérégulations des voies apoptotiques, TGFβ ou<p>9<p>encore de signalisation intracellulaire altèrent l’homéostasie des cellules T CD3−CD4+ pouvant favoriser la perte de la capacité apoptotique et/ou la croissance cellulaire. Cette signature moléculaire a été étendue par l’identification de 20 microARNs dont l’expression est dérégulée dans les cellules T CD3−CD4+ d’une cohorte de 6 patients. Par ailleurs, la modification de l’expression des récepteurs impliqués dans la migration leucocytaire au cours de l’évolution de P1 pourrait expliquer l’infiltration ganglionnaire des cellules T clonales et la progression du lymphome.<p>La caractérisation des désordres cytogénétiques et moléculaires des cellules T CD3−CD4+ chez les patients L-SHE permettrait à terme d’identifier de nouveaux marqueurs diagnostiques et contribuer ainsi au développement de nouvelles cibles thérapeutiques dans une grande diversité de pathologies lymphoprolifératives de type Th2. / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished

The doctoral thesis MD. Liubov Kastnerova (previous name Kyrpychova) is focused on the histomorphological and molecular biologic features of selected cutaneous epithelial and nonepithelial tumors and is structured as a commentary to the 20 articles published during four years, representing the completed scientific projects in the Ph.D. course. In eight papers, the author of the thesis is the first author, whereas she coauthored in the remaining 12 papers. The thesis is composed of the commented files of authors own publications and it is divided into cutaneous epithelial and nonepithelial tumors. The first section, «Cutaneous epithelial tumors», includes 14 articles that are subdivided into two parts: adnexal tumors (9 articles) and lesions of anogenital mammary-like glands (5 articles). Of the nine articles on adnexal tumors, there are 5 articles focused on various benign and malignant adnexal lesions with apocrine or eccrine differentiation. Novel findings in this part include the identification of hitherto unreported alterations of the MYBL1 gene in adenoid cystic carcinoma of the skin and lack of deletion of the 1p36 locus in this neoplasm; the lack of a correlation between cellular composition and the presence CRTC1-MAML2 fusions in hidradenoma, the absence of CRTC3-MAML2 fusions in this tumor,...